Sareum Holdings (SAR)


SAR Share PerformanceMore

52 week high1.7250 28/09/16
52 week low0.1733 04/01/16
52 week change 0.5350 (281.58%)
4 week volume190,621,724 13/11/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Directors' Remuneration & General Meeting

RNS Number: 0044R Sareum Holdings PLC 06 December 2016 (AIM: SAR) 6 December 2016 SAREUM HOLDINGS PLC ("Sareum" or the "Company") Directors' Remuneration & General Meeting Introduction Further to the announcement by Sareum of the licensing of CCT245737 to ProNAi Therapeutics, Inc. (the "ProNAi licensing transaction") on 27 September ...

Sareum to Present at AACR-NCI-EORTC Conference

RNS Number: 3564Q Sareum Holdings PLC 29 November 2016 (AIM: SAR) 29 November 2016 SAREUM HOLDINGS PLC ("Sareum" or the "Company") Sareum to Present TYK2 Cancer Research Programme at the 2016 AACR-NCI-EORTC International Conference Sareum Holdings plc, the specialist cancer drug discovery and development business, is pleased to a...

Notice of AGM

RNS Number: 6260P Sareum Holdings PLC 21 November 2016 (AIM: SAR) 21 November 2016 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Notice of AGM The Company announces that a notice has been sent to its shareholders to convene its Annual General Meeting ("AGM") which is to be held at 10.00 a.m. on 15 December 2016 at the offices of WH Ir...

Sareum Holdings narrows FY pretax loss

Sareum Holdings has narrowed its FY pretax loss to 1.2m, from a year-earlier loss of 1.4m. Revenue was nil and most of los...

Final Results

RNS Number: 0469O Sareum Holdings PLC 02 November 2016 (AIM: SAR) 2 November 2016 Sareum Holdings plc ("Sareum" or "the Company") Final Results Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business , is pleased to announce its final results for the year ended 30 June 2016. Financial highlights Net assets at year-e...

Sareum says TYK2 feasibility study successful

Sareum Holdings announces the successful conclusion from its feasibility study into the potential for its TYK2 programm...

Successful Outcome from TYK2 Feasibility Study

RNS Number: 2319N Sareum Holdings PLC 24 October 2016 (AIM: SAR) 24 October 2016 SAREUM HOLDINGS PLC ("Sareum" or "the Company") SUCCESSFUL OUTCOME FROM TYK2 CANCER FEASIBILITY STUDY Study part funded by 140,000 award from the Innovate UK BioMedical Catalyst Positive result supports case to advance programme further ...

Sareum notes Japan, Singapore Patent Grants

Sareum said the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions as...

Fundamental DataMore

Dividend yield0 %

Equity Research (SAR)

Sareum Holdings plc
The specialist cancer drug discovery and development business has announced final results for the year ending 30 June 2016. It is a year that saw the Company get its first clinical trial approvals...
Sareum Holdings plc
Followers of the specialist cancer drug discovery and development Company were rewarded for their patience at the end of May this year when its CHK1 inhibitor programme saw a candidate (CCT245737)...
hardman & co
Sareum Holdings plc
Sareum is a specialist small molecule drug discovery and development company with programs in oncology and inflammatory disorders. Sareum is virtual, using collaborators and contract research...

Latest discussion posts More

  • directors bonus

    I would like to propose a bonus of #50,000 to every shareholder, not in anticipation of anything, but to reward them for sticking with a company which has been loosing value ...
    IB Investor
  • Re: Another 200% up....

    Hey I seem to invest in most the BB's where you've said the same R94! Does this mean I've terrible investment skills!!!? Hang in there LTH & good luck.
  • Re: Another 200% up....

    Tom Winnifrith eh? There's a man whose t1ps cost me a pretty penny in days gone by.

Users' HoldingsMore

Users who hold Sareum Holdings also hold..

Codes & Symbols